<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Bakker, C.E.</title>
    <link>http://repub.eur.nl/res/aut/23145/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Exceptional good cognitive and phenotypic profile in a male carrying a mosaic mutation in the FMR1 gene (Article)</title>
      <link>http://repub.eur.nl/res/pub/35274/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>Fragile X (FRAX) syndrome is a commonly inherited form of mental retardation resulting from the lack of expression of the fragile X mental retardation protein (FMRP). It is caused by a stretch of CGG repeats within the fragile X gene, which can be unstable in length as it is transmitted from generation to generation. Once the repeat exceeds a threshold length, the FMR1 gene is methylated and no protein is produced resulting in the fragile X phenotype. The consequences of FMRP absence in the mechanisms underlying mental retardation are unknown. We have identified a male patient in a classical FRAX family without the characteristic FRAX phenotype. His intelligence quotient (IQ) is borderline normal despite the presence of a mosaic pattern of a pre-mutation (25%), full mutation (60%) and a deletion (15%) in the FMR1 gene. The cognitive performance was determined at the age of 28 by the Raven test and his IQ was 81. However, FMRP expression studies in both hair roots and lymphocytes, determined at the same time as the IQ test, were within the affected male range. The percentage of conditioned responses after delay eyeblink conditioning was much higher than the average percentage measured in FRAX studies. Moreover, this patient showed no correlation between FMRP expression and phenotype and no correlation between DNA diagnostics and phenotype. </description>
    </item> <item>
      <title>Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation (Article)</title>
      <link>http://repub.eur.nl/res/pub/10782/</link>
      <pubDate>2007-01-15T00:00:00Z</pubDate>
      <description>The human FMR1 gene contains a CGG repeat in its 5′ untranslated region. The repeat length
in the normal population is polymorphic (5–55 CGG repeats). Lengths beyond 200 CGGs (full
mutation) result in the absence of the FMR1 gene product, FMRP, through abnormal
methylation and gene silencing. This causes Fragile X syndrome, the most common
inherited form of mental retardation. Elderly carriers of the premutation, defined as a repeat
length between 55 and 200 CGGs, can develop a progressive neurodegenerative syndrome:
Fragile X-associated tremor/ataxia syndrome (FXTAS). In FXTAS, FMR1 mRNA levels are
elevated and it has been hypothesised that FXTAS is caused by a pathogenic RNA gain-offunction
mechanism. We have developed a knock in mouse model carrying an expanded
CGG repeat (98 repeats), which shows repeat instability and displays biochemical,
phenotypic and neuropathological characteristics of FXTAS. Here, we report further
repeat instability, up to 230 CGGs. An expansion bias was observed, with the largest
expansion being 43 CGG units and the largest contraction 80 CGG repeats. In humans, this
length would be considered a full mutation and would be expected to result in gene
silencing. Mice carrying long repeats (∼230 CGGs) display elevated mRNA levels and
decreased FMRP levels, but absence of abnormal methylation, suggesting that modelling the
Fragile X full mutation in mice requires additional repeats or other genetic manipulation.</description>
    </item> <item>
      <title>Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes (Article)</title>
      <link>http://repub.eur.nl/res/pub/35639/</link>
      <pubDate>2007-01-01T00:00:00Z</pubDate>
      <description>The Fmr1 knockout (KO) mouse is characterized by an increased audiogenic seizure (AGS) susceptibility and is considered a good animal model for epilepsy and seizures in the human fragile-X (FRAX) syndrome. Here, we tested the hypothesis that the reintroduction of the FMR1 gene is able to revert the AGS susceptibility characterizing Fmr1 KO mice. To this aim, two groups of Fmr1 KO transgenic mice, which have additional copies of the human FMR1 gene (YAC) or FMR1 cDNA (G6) were used. AGS susceptibility of these mice was examined and compared to that of Fmr1 KO, wild type, and wild-type animals in whom the FMR1gene was also introduced (over-expressed). Mice were tested at different ages because AGS susceptibility is age dependent. The intensity of response was scored and the results were analyzed by means of 2-way analysis of variance to evaluate the effects of age and genetic condition. We found that AGS susceptibility rescue is complete in the G6 mice and partial in YAC mice. Our data indicate that the introduction of the human FMR1 gene in Fmr1 KO mice is able to revert the Fmr1 KO epileptic phenotype. </description>
    </item> <item>
      <title>Knockout mouse model for Fxr2: a model for mental retardation (Article)</title>
      <link>http://repub.eur.nl/res/pub/9866/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is a common form of mental retardation caused by the
      absence of the FMR1 protein, FMRP. Fmr1 knockout mice exhibit a phenotype
      with some similarities to humans, such as macro-orchidism and behavioral
      abnormalities. Two homologs of FMRP have been identified, FXR1P and FXR2P.
      These proteins show high sequence similarity, including all functional
      domains identified in FMRP, such as RNA binding domains. They have an
      overlap in tissue distribution to that of FMRP. Interactions between the
      three FXR proteins have also been described. FXR2P shows high expression
      in brain and testis, like FMRP. To study the function of FXR2P, we
      generated an Fxr2 knockout mouse model. No pathological differences
      between knockout and wild-type mice were found in brain or testis. Given
      the behavioral phenotype in fragile X patients and the phenotype
      previously reported for the Fmr1 knockout mouse, we performed a thorough
      evaluation of the Fxr2 knockout phenotype using a behavioral test battery.
      Fxr2 knockout mice were hyperactive (i.e. traveled a greater distance,
      spent more time moving and moved faster) in the open-field test, impaired
      on the rotarod test, had reduced levels of prepulse inhibition, displayed
      less contextual conditioned fear, impaired at locating the hidden platform
      in the Morris water task and were less sensitive to a heat stimulus.
      Interestingly, there are some behavioral phenotypes in Fxr2 knockout mice
      which are similar to those observed in Fmr1 knockout mice, but there are
      also some different behavioral abnormalities that are only observed in the
      Fxr2 mutant mice. The findings implicate a role for Fxr2 in central
      nervous system function.</description>
    </item> <item>
      <title>Instability of a (CGG)98 repeat in the Fmr1 promoter (Article)</title>
      <link>http://repub.eur.nl/res/pub/9699/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is one of 14 trinucleotide repeat diseases. It arises
      due to expansion of a CGG repeat which is present in the 5'-untranslated
      region of the FMR1 gene, disruption of which leads to mental retardation.
      The mechanisms involved in trinucleotide repeat expansion are poorly
      understood and to date, transgenic mouse models containing transgenic
      expanded CGG repeats have failed to reproduce the instability seen in
      humans. As both cis-acting factors and the genomic context of the CGG
      repeat are thought to play a role in expansion, we have now generated a
      knock-in mouse Fmr1 gene in which the murine (CGG)8 repeat has been
      exchanged with a human (CGG)98 repeat. Unlike other CGG transgenic models,
      this model shows moderate CGG repeat instability upon both in maternal and
      paternal transmission. This model will now enable us to study the timing
      and the mechanism of repeat expansion in mice.</description>
    </item> <item>
      <title>The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/9408/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is caused by the absence of the fragile X
          mental-retardation protein (FMRP). FMRP and the fragile X-related proteins
          1 and 2 (FXR1P and FXR2P) form a gene family with functional similarities,
          such as RNA binding, polyribosomal association and nucleocytoplasmic
          shuttling. In a previous study, we found that FMRP and FXR1P shuttle
          between cytoplasm and nucleoplasm, while FXR2P shuttles between cytoplasm
          and nucleolus. The nuclear and nucleolar-targeting properties of these
          proteins were investigated further. Here, we show that FXR2P contains in
          its C-terminal part, a stretch of basic amino acids 'RPQRRNRSRRRRFR' that
          resemble the nucleolar-targeting signal (NoS) of the viral protein Rev.
          This particular sequence is also present within exon 15 of the FXR1 gene.
          This exon undergoes alternative splicing and is therefore only present in
          some of the FXR1P isoforms. We investigated the intracellular distribution
          of various FXR1P isoforms with (iso-e and iso-f) and without (iso-d) the
          potential NoS in transfected COS cells treated with the nuclear export
          inhibitor leptomycin-B. Both iso-e and iso-f showed a nucleolar
          localization, as observed for FXR2P; iso-d was detected in the
          nucleo-plasm outside the nucleoli. Further, when a labelled 16-residue
          synthetic peptide corresponding to the NoS of FXR1P was added to human
          fibroblast cultures a clear nucleolar signal was observed. Based on these
          data we argue that the intranuclear distribution of FXR2P and FXR1P
          isoforms is very likely to be mediated by a similar NoS localized in their
          C-terminal region. This domain is absent in some FXR1P isoforms as well as
          in all FMRP isoforms, suggesting functional differences for this family of
          proteins, possibly related to RNA metabolism in different tissues.</description>
    </item> <item>
      <title>Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations (Article)</title>
      <link>http://repub.eur.nl/res/pub/9073/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Fragile X syndrome is caused by the absence of the fragile X mental
          retardation protein (FMRP). FMRP and its structural homologues FXR1P and
          FXR2P form a family of RNA-binding proteins (FXR proteins). The three
          proteins associate with polyribosomes as cytoplasmic mRNP particles. Here
          we show that small amounts of FMRP, FXR1P and FXR2P shuttle between
          cytoplasm and nucleus. Mutant FMRP of a severely affected fragile X
          patient (FMRPI304N) does not associate with polyribosomes and shuttles
          more frequently than normal FMRP, indicating that the association with
          polyribosomes regulates the shuttling process. Using leptomycin B we
          demonstrate that transport of the FXR proteins out of the nucleus is
          mediated by the export receptor exportin1. Finally, inactivation of the
          nuclear export signal in two FXR proteins shows that FMRP shuttles between
          cytoplasm and nucleoplasm, while FXR2P shuttles between cytoplasm and
          nucleolus. Therefore, molecular dissection of the shuttling routes used by
          the FXR proteins suggests that they transport different RNAs.</description>
    </item> <item>
      <title>Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P (Article)</title>
      <link>http://repub.eur.nl/res/pub/9181/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>The absence of fragile-X mental-retardation protein (FMRP) results in
          fragile-X syndrome. Two other fragile-X-related (FXR) proteins have been
          described, FXR1P and FXR2P, which are both very similar in amino acid
          sequence to FMRP. Interaction between the three proteins as well as with
          themselves has been demonstrated. The FXR proteins are believed to play a
          role in RNA metabolism. To characterize a possible functional role of the
          interacting proteins the complex formation of the FXR proteins was studied
          in mammalian cells. Double immunofluorescence analysis in COS cells
          over-expressing either FMRP ISO12/FXR1P or FMRP ISO12/FXR2P confirmed
          heterotypic interactions. However, Western-blotting studies on cellular
          homogenates containing physiological amounts of the three proteins gave
          different indications. Gel-filtration experiments under physiological as
          well as EDTA conditions showed that the FXR proteins were in complexes of
          &gt;600 kDa, as parts of messenger ribonuclear protein (mRNP) particles
          associated with polyribosomes. Salt treatment shifted FMRP, FXR1P and
          FXR2P into distinct intermediate complexes, with molecular masses between
          200 and 300 kDa. Immunoprecipitations of FMRP as well as FXR1P from the
          dissociated complexes revealed that the vast majority of the FXR proteins
          do not form heteromeric complexes. Further analysis by [(35)S]methionine
          labelling in vivo followed by immunoprecipitation indicated that no
          proteins other than the FXR proteins were present in these complexes.
          These results suggest that the FXR proteins form homo-multimers
          preferentially under physiological conditions in mammalian cells, and
          might participate in mRNP particles with separate functions.</description>
    </item> <item>
      <title>Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/8754/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Glycogen storage disease type II (GSDII; Pompe disease), caused by
          inherited deficiency of acid alpha-glucosidase, is a lysosomal disorder
          affecting heart and skeletal muscles. A mouse model of this disease was
          obtained by targeted disruption of the murine acid alpha-glucosidase gene
          (Gaa) in embryonic stem cells. Homozygous knockout mice (Gaa -/-) lack Gaa
          mRNA and have a virtually complete acid alpha-glucosidase deficiency.
          Glycogen-containing lysosomes are detected soon after birth in liver,
          heart and skeletal muscle cells. By 13 weeks of age, large focal deposits
          of glycogen have formed. Vacuolar spaces stain positive for acid
          phosphatase as a sign of lysosomal pathology. Both male and female
          knockout mice are fertile and can be intercrossed to produce progeny. The
          first born knockout mice are at present 9 months old. Overt clinical
          symptoms are still absent, but the heart is typically enlarged and the
          electrocardiogram is abnormal. The mouse model will help greatly to
          understand the pathogenic mechanism of GSDII and is a valuable instrument
          to explore the efficacy of different therapeutic interventions.</description>
    </item> <item>
      <title>Macroorchidism in FMR1 knockout mice is caused by increased Sertoli cell proliferation during testicular development (Article)</title>
      <link>http://repub.eur.nl/res/pub/8756/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>The fragile X syndrome is the most frequent hereditary form of mental
          retardation. This X-linked disorder is, in most cases, caused by an
          unstable and expanding trinucleotide CGG repeat located in the
          5'-untranslated region of the gene involved, the fragile X mental
          retardation 1 (FMR1) gene. Expansion of the CGG repeat to a length of more
          than 200 trinucleotides results in silencing of the FMR1 gene promoter
          and, thus, in an inactive gene. The clinical features of male fragile X
          patients include mental retardation, autistiform behavior, and
          characteristic facial features. In addition, macroorchidism is observed.
          To study the role of Sertoli cell proliferation and FSH signal
          transduction in the occurrence of macroorchidism in fragile X males, we
          made use of an animal model for the fragile X syndrome, an Fmr1 knockout
          mouse. The results indicate that in male Fmr1 knockout mice, the rate of
          Sertoli cell proliferation is increased from embryonic day 12 to 15 days
          postnatally. The onset and length of the period of Sertoli cell
          proliferation were not changed compared with those in the control males.
          Serum levels of FSH, FSH receptor messenger RNA expression, and short term
          effects of FSH on Sertoli cell function, as measured by down-regulation of
          FSH receptor messenger RNA, were not changed. We conclude that
          macroorchidism in Fmr1 knockout male mice is caused by an increased rate
          of Sertoli cell proliferation. This increase does not appear to be the
          result of a major change in FSH signal transduction in Fmr1 knockout mice.</description>
    </item>
  </channel>
</rss>